DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Recommendation of “Hold” from Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been given a consensus rating of “Hold” by the seven research firms that are covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company.

DSRLF has been the topic of several analyst reports. UBS Group lowered DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a research note on Wednesday, June 17th. Zacks Research upgraded DiaSorin to a “hold” rating in a research note on Tuesday, May 12th. Piper Sandler began coverage on DiaSorin in a report on Thursday, June 11th. They set a “neutral” rating on the stock. Finally, BNP Paribas Exane downgraded shares of DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th.

DiaSorin Price Performance

DiaSorin stock opened at $81.00 on Tuesday. DiaSorin has a 12-month low of $66.50 and a 12-month high of $100.00. The firm’s fifty day moving average price is $78.65 and its 200 day moving average price is $76.64.

About DiaSorin

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.